Effects of clinical laboratory choice on study outcome: An interlaboratory evaluation of aminotransferase levels

Pharmacotherapy

Volumn 28, Issue 4, 2008, Pages 453-457

  Green, Jody L ^a,b   Campagna, Elizabeth ^a   Bogdan, Gregory M ^a   Dart, Richard C ^a   Heard, Kennon ^a  

^a ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^b MC 0180 ^*  (United States)

Author keywords

Alanine aminotransferase; ALT; Clinical laboratory techniques; Liver; Systematic bias; ULRR; Upper limit of reference range

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL LABORATORY; CONFIDENCE INTERVAL; ENZYME ACTIVATION; FEMALE; HUMAN; LABORATORY APPARATUS, EQUIPMENT AND SUPPLIES; MALE; METHODOLOGY; OUTCOME ASSESSMENT; SAMPLING; SERUM; SEX DIFFERENCE;

ADULT; ALANINE TRANSAMINASE; BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING;

EID: 41549153801     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.4.453     Document Type: Article

References (6)

1. CDER-PHRMA-AASLD Conference 2000. Drug-induced liver injury: a national and global problem. Clinical white paper, preconference study document; FDA working group (CDER-PHRMA-AASLD) 2000;1-13. Available from www.fda.gov/cder/livertox/clinical.pdf. Accessed October 8, 2007.
2. Sasse EA, Doumas BT, Miller WG, et al. How to define and determine reference intervals in the clinical laboratory; approved guideline, second edition. NCCLS document C28-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2000. Available from www.clsi.org/source/orders/free/c28-a2.pdf. Accessed October 8, 2007.
3. Kuffner EK, Green JL, Bogdan GM, et al. The effect of acetaminophen (4 grams a day for 3 consecutive days) on hepatic tests in alcoholic patients: a multicenter randomized study [online exclusive article]. BMC Med 2007;5:13. Available from http://www.biomedcentral.com/1741-7015/5/13.
4. Piton A, Poynard T, Imbert-Bismut F, et al, for the MULTIVIRC Group. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998;27:1213-19.
5. Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease [online exclusive article]. Comp Hepatol 2002;1:3. Available from http://www.comparative-hepatology.com/content/1/1/3.
6. Rustad P, Felding P, Lahti A, Hyltoft Petersen P. Descriptive analytical data and consequences for calculation of common reference intervals in the Nordic reference interval project 2000. Scand J Clin Lab Invest 2004;64:343-70.